Regeneron Pharmaceuticals Inc. (REGN) Q1 2026 (USD): EPS 9.47 (exp. 8.80), Revenue 3.61bln (exp. 3.47bln)
Sales Breakdown (USD)
- Dupizent 4.9bln, +33%
Context
Regeneron Pharmaceuticals' Q1 2026 earnings report reveals a notable earnings per share (EPS) of $9.47, outperforming expectations of $8.80, and revenue of $3.61 billion, surpassing the forecast of $3.47 billion. The strong performance is largely driven by a 33% increase in sales of Dupizent, indicating robust demand and potential for future growth, which may positively influence sentiment toward biotech stocks and attract investor interest in the sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#FRANCE#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#REGENERON PHARMACEUTICALS INC#REGN.US#SANOFI#SAN.FP#BANCO SANTANDER SA#FOREX#EQUITIES#METALS#EU SESSION#BIOTECHNOLOGY#PHARMACEUTICALS#DIVERSIFIED BANKS#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#S&P 500 INDEX#CAC 40 INDEX#NASDAQ 100 INDEX#SANOFI SA#REGN#DXY#US EQUITIES